Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC.

Haematologica. 2019 Dec 26. pii: haematol.2019.235648. doi: 10.3324/haematol.2019.235648. [Epub ahead of print]

2.

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH.

Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18.

PMID:
31297883
3.

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC.

Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.

Supplemental Content

Loading ...
Support Center